Literature DB >> 17598591

Memory performance in HIV/AIDS--a prospective case control study.

Francis E Odiase1, Olubunmi A Ogunrin, Adesola A Ogunniyi.   

Abstract

BACKGROUND: Memory impairment, usually impaired retrieval of information, has been described in HIV/AIDS, especially among those with severe illness. Neuro-cognitive disturbances in HIV/AIDS have been linked to poor quality of life and medication adherence. This prospective, case-control study was designed to assess the verbal and non-verbal memory as well as the attention abilities of Nigerian Africans with HIV/AIDS and correlate their performances with their CD4+ T lymphocytes (CD4+) counts.
METHODS: A total of 288 randomly selected subjects, comprising 96 HIV-positive symptomatic patients, 96 HIV-positive asymptomatic patients and 96 HIV-negative controls, participated in the study. The subjects were age-, sex-, and level of education matched. The Recognition Memory Test and Choice Reaction Time tasks, components of the computer-assisted neuropsychological tests battery- the Iron Psychology 'FePsy' were used for cognitive assessments.
RESULTS: The mean memory scores of the HIV-positive asymptomatic subjects did not differ significantly from the controls (p > 0.05) but the HIV-positive symptomatic subjects' scores were significantly lower than the controls (p < 0.05). Both HIV-positive groups had psychomotor slowing and impaired attention (p < 0.05). The HIV-positive subjects with CD4+ counts < 200/microl and between 200 and 499/microl had significant memory impairment (p < 0.001 and p < 0.001 respectively) but there was no significant impairment among those with count > or = 500/microl. Impaired ability for sustained attention was however present irrespective of the CD4+ level relative to controls (p < 0.001).
CONCLUSIONS: We concluded that there was no significant memory disturbance among HIV-positive asymptomatic subjects despite the presence of impaired attention and psychomotor slowing, and that the severity of immune suppression (as indicated by the CD4+ T lymphocytes count) is a strong determinant of cognitive decline in HIV/AIDS.

Entities:  

Mesh:

Year:  2007        PMID: 17598591     DOI: 10.1017/s0317167100005977

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  11 in total

1.  Socioeconomic Status and Neuropsychological Functioning: Associations in an Ethnically Diverse HIV+ Cohort.

Authors:  Alyssa Arentoft; Desiree Byrd; Jennifer Monzones; Kelly Coulehan; Armando Fuentes; Ana Rosario; Caitlin Miranda; Susan Morgello; Monica Rivera Mindt
Journal:  Clin Neuropsychol       Date:  2015-04-14       Impact factor: 3.535

2.  Associations of cardiovascular variables and HAART with cognition in middle-aged HIV-infected and uninfected women.

Authors:  Howard A Crystal; Jeremy Weedon; Susan Holman; Jennifer Manly; Victor Valcour; Mardge Cohen; Kathryn Anastos; Chenglong Liu; Wendy J Mack; Elizabeth Golub; Jason Lazar; Ann Ho; Mary Jeanne Kreek; Robert C Kaplan
Journal:  J Neurovirol       Date:  2011-10-18       Impact factor: 2.643

3.  Antiretroviral adherence and the nature of HIV-associated verbal memory impairment.

Authors:  Matthew J Wright; Ellen Woo; Jessica Foley; Mark L Ettenhofer; Maria E Cottingham; Amanda L Gooding; Jiah Jang; Michelle S Kim; Steve A Castellon; Eric N Miller; Charles H Hinkin
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

Review 4.  Epidemiology of neurodegenerative diseases in sub-Saharan Africa: a systematic review.

Authors:  Alain Lekoubou; Justin B Echouffo-Tcheugui; Andre P Kengne
Journal:  BMC Public Health       Date:  2014-06-26       Impact factor: 3.295

5.  Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection.

Authors:  Bing Sun; Linda Abadjian; Hans Rempel; Cyrus Calosing; Johannes Rothlind; Lynn Pulliam
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

Review 6.  HIV Antiretroviral Medication Neuropenetrance and Neurocognitive Outcomes in HIV+ Adults: A Review of the Literature Examining the Central Nervous System Penetration Effectiveness Score.

Authors:  Alyssa Arentoft; Katie Troxell; Karen Alvarez; Maral Aghvinian; Monica Rivera Mindt; Mariana Cherner; Kathleen Van Dyk; Jill Razani; Michaela Roxas; Melissa Gavilanes
Journal:  Viruses       Date:  2022-05-26       Impact factor: 5.818

7.  HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon.

Authors:  Georgette D Kanmogne; Callixte T Kuate; Lucette A Cysique; Julius Y Fonsah; Sabine Eta; Roland Doh; Dora M Njamnshi; Emilienne Nchindap; Donald R Franklin; Ronald J Ellis; John A McCutchan; Fidele Binam; Dora Mbanya; Robert K Heaton; Alfred K Njamnshi
Journal:  BMC Neurol       Date:  2010-07-13       Impact factor: 2.474

Review 8.  Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration?

Authors:  P P Koopmans; R Ellis; B M Best; S Letendre
Journal:  Neth J Med       Date:  2009-06       Impact factor: 1.422

9.  Cognitive function in patients with newly diagnosed HIV infection in a tertiary health facility in south - west Nigeria: Assessment using computer-assisted neuropsychological test battery.

Authors:  Taofiki A Sunmonu; Olubunmi A Ogunrin; Frank A Imarhiagbe; Lukman F Owolabi; Morenikeji A Komolafe; Olayinka S Llesanmi
Journal:  eNeurologicalSci       Date:  2016-02-24

10.  Effect of vinpocetine (cognitol™) on cognitive performances of a nigerian population.

Authors:  Ao Ogunrin
Journal:  Ann Med Health Sci Res       Date:  2014-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.